Research progress of adalimumab in pediatric Crohn ′s disease / 国际儿科学杂志
International Journal of Pediatrics
;
(6): 657-660, 2019.
Article
Dans Chinois
| WPRIM
| ID: wpr-798206
ABSTRACT
Adalimumab is an anti-TNF-α recombinant IgG1, a fully humanized monoclonal antibody binding soluble human tumor necrosis factor alpha with high affinity and specificity.It has lower immunogenicity and can be used clinically for induction and maintenance of remission in Crohn′s disease.The effectiveness, sustainability and safety of adalimumab in the treatment of pediatric Crohn′s disease has been gradually confirmed, which may pave the way for new therapy to treat children with refractory Crohn′s disease.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
International Journal of Pediatrics
Année:
2019
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS